This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

WellPoint's Deal for Amerigroup Is Landmark 'Obamacare' Merger

Updated to include Moody's rating downgrade, Fitch and S&P actions.

NEW YORK ( TheStreet) -- Obamacare has its first major merger, after health care giant WellPoint (WLP) said on Monday that it will buy Amerigroup (AGP), a managed health care company with 4.5 million customers of state sponsored health care programs, for $4.9 billion, or $92 a share in cash.

The deal, which comes at a 43% premium to Amerigroup's Friday closing share price, is the first major health care sector merger since President Obama's Affordable Health Care Act was narrowly upheld by the Supreme Court in late June and adds to a trend of consolidation within the industry.

For WellPoint, which ended 2011 with 65-plus million health care customers including those under Blue Cross and Blue Shield private plans that it is a licensee of, Amerigroup's mostly Medicaid customers will help the company push into state sponsored health care plans that are most impacted by the health care act and court ruling.

Forget the SCOTUS decision, the market has already changed for healthcare stocks

"We believe that this combination will create an industry leader in the government sector serving Medicaid and Medicare enrollees," said WellPoint CEO Angela Braly in a statement. Braly added that the merger, which focuses on Medicaid recipients like the poor and the elderly, is an opportunity to "position our companies for future growth as the health insurance industry changes and as we prepare for health insurance exchanges."

With Amerigroup, WellPoint's Medicaid footprint will be in 19 states, gaining 4.5 million accounts and some dual eligible managed care accounts. The company projects that it will also gain access to $105 billion in annual dual eligible spending opportunities in the four largest states where it's gaining such a presence.

Amerigroup shares rose nearly 40% to over $89.84 a share in early Monday trading on news of the deal, while WellPoint shares climbed nearly 3% to $61.64 a share. Prior to the deal, both companies' shares had declined on the Supreme Court's ruling in June 28.

News of the deal caused some Medicaid-focused healthcare providers such as Centene (CNC), Molina Healthcare (MOH) and WellCare Health Partners (WCG) to surge over 10% in early trading, as some expect continued consolidation.

"Expect other companies with government exposure to see greater investor interest," wrote Credit Suisse analyst Charles Boorady in a note to clients, highlighting Centene, Molina Healthcare, Humana (HUM), Coventry Healthcare (CVH) and Health Net (HNT) as other healthcare providers with highe Medicaid and Mecidare exposure.

While WellPoint executives indicated on a conference call outlining the deal that they would have done the merger with or without the expansion of healthcare reform, Bank of American Merrill Lynch analyst Kevin Fishbeck said that a key to the merger will be gaining access to dual eligible customers of Medicare and Medicaid, who can be among the costliest to insure.

" The company highlighted that new business wins in the duals could be dilutive initially, and then ramp up," Fishbeck in a note to clients, who supported WellPoint's announced synergy and earnings projections from the deal.

As investors position on the Supreme Court's landmark health care decision, they may be wise to spend their time understanding how consistent M&A trends are already consolidating the health care sector, with deals like WellPoint's acquisition of Amerigroup expected in coming quarters and years.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
WLP $136.01 1.43%
WAG $81.65 2.05%
CIG $4.67 0.00%
DVA $84.09 0.00%
AAPL $132.54 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs